The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
Infectivity of the Plasmodium falciparum NF54 malaria cell bank, MCB-002, in humans
Scientific title
Characterisation of the in vivo infectivity of the Plasmodium falciparum NF54 cell bank, MCB-002, in malaria naive adults
Secondary ID [1] 281445 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 287706 0
Condition category
Condition code
Infection 288043 288043 0 0
Studies of infection and infectious agents

Study type
Description of intervention(s) / exposure
Human red blood cells infected with Plasmodium falciparum NF54
Dose: 1,800 viable Plasmodium falciparum infected red blood cells
Mode of administration: intra-venous injection
Duration: one injection at Day 0
Patients will be actively monitored up to Day 28 post injection. A blood sample will be collected on Day 90 post infection for safety serum.
Intervention code [1] 285951 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 288254 0
Primary Outcome 1: In vivo infectivity of the P. falciparum NF54 cell bank, MCB-002 in humans.
Assessed by Thick blood smear and polymerase chain reaction
Timepoint [1] 288254 0
Day 3-Day 11 post administration of P. falciparum infected red blood cells
Primary outcome [2] 288255 0
Primary Outcome 2: Safety of the P. falciparum NF54 cell bank, MCB-002 in humans
Assessed by frequency and type of clinical adverse events, hematology, blood chemistry, serology, physical examination including vital signs and electrocardiograms
Timepoint [2] 288255 0
Day 0-D90 post administration of P. falciparum infected red blood cells
Secondary outcome [1] 299699 0
Secondary Outcome 1: Immunogenicity of the P. falciparum NF54 cell bank, MCB-002 in humans
Assessed by measuring malaria-specific antibody responses and T cell responses
Timepoint [1] 299699 0
D0, D3-8, D28 and D90.

Key inclusion criteria
1. Males aged 18-45yrs who do not live alone from D1 until at least the end of anti-malarial treatment
2. Body Mass Index within range of 18-30
3. Contactable and available for the duration of the trial (90 days)
4. Non-smokers and in good health as assessed during pre-study medical examination and by review of screening results
5. Good peripheral venous access
Minimum age
18 Years
Maximum age
45 Years
Can healthy volunteers participate?
Key exclusion criteria
1. History of malaria.
2. Travelled to or lived (>2 weeks) in a malaria-endemic country during the past 12 months or planned travel to a malaria-endemic country during the course of the study.
3. Has evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk) as determined by the method of Gaziano et al. Risk factors include sex, age, systolic blood pressure (mm Hg), smoking status, body mass index (BMI, kg/mm2), reported diabetes status and blood pressure.
4. History of splenectomy.
5. History of a severe allergic reaction, anaphylaxis or convulsions following any vaccination, infusion or treatment with the anti-malarial drugs artemether and/or lumefantrine.
6. Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease (HIV or other immunodeficiencies), insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, psoriasis, rheumatoid arthritis, asthma, epilepsy or obsessive compulsive disorder, skin carcinoma excluding non-spreadable skin cancers such as basal cell and squamous cell carcinoma.
7. Known inherited genetic anomaly (known as cytogenetic disorders) e.g., Down’s syndrome.
8. Individuals wishing to donate blood to the Australian Red Cross Blood Service during the study or within 6 months of administration of the malaria inoculum.
9. The volunteer has a diagnosis of schizophrenia, severe depression, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis. Participants who are receiving a single antidepressant drug and are stable for at least 3 months prior to enrollment without decompensating may be allowed to enroll in the study at the investigator’s discretion.
10. Known pre-existing prolongation of the QTc interval. Family history of congenital prolongation of the QTc interval on electrocardiograms or of sudden death or any other clinical condition known to prolong the QTc interval, e.g. volunteers with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.
11. Recent or current therapy with an antibiotic or drug with potential anti-malarial activity (tetracycline, azthromycin, clindamycin, hydroxychloroquine etc).
12. Concomitant use of any drug which is metabolised by the cytochrome enzyme CYP2D6 (e.g. flecainide, metoprolol, imipramine, amitriptyline, clomipramine) OR drugs that are known to prolong the QTc interval, e.g. antiarrhythmics of classes IA and III, neuroleptics, antidepressant agents, certain antibiotics (including some agents of the following classes: macrolides, fluoroquinolones, imidazole and triazole antifungal agents), certain nonsedating antihistamines (terfenadine, astemizole), cisapride.
13. Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or anticoagulants. Currently receiving or have previously received immunosuppressive therapy, including systemic steroids including ACTH or inhaled steroids in dosages which are associated with hypothalamic-pituitary-adrenal axis suppression such as 1mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency corticosteroids (budesonide 800 microgram per day or fluticasone 750 microgram).
14. Presence of acute infectious disease or fever (e.g., sub-lingual temperature greater than or equal to 38.5 degrees celsius) within the five days prior to study product administration).
15. Evidence of acute illness within the four weeks before trial prior to screening.
16. Significant intercurrent disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.
17. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
18. A history of drug habituation, or any prior intravenous usage of an illicit substance.
19. Medical requirement for intravenous immunoglobulin or blood transfusions.
20. Participation in any investigational product study within the 8 weeks preceding the study.
21. Participation in any research study involving significant blood sampling, or blood donation to Red Cross (or other) blood bank during the 8 weeks preceding the reference drug dose in the study.
22. Have ever received a blood transfusion.
23. Positive test for HIV, Hepatitis B, hepatitis C, Human T-cell Lymphotropic Virus I & II (HTLVI & HTLVII), and syphilis.
24. Any clinically significant biochemical or haematologic abnormality (Hb must begreater than or equal to 13.5g/dL).
25. Ingestion of any poppy seeds within the 48 hours prior to the screening blood test
(volunteers will be advised by phone not to consume any poppy seed in this time period).
26. Detection of any drug listed Appendix 3 "Laboratory Values" in the urine drug screen unless there is an explanation acceptable to the medical investigator (e.g. the subject has stated in advance that they consumed a prescription or OTC product which contained the detected drug) and/or the subject has a negative urine drug screen on retest by the pathology laboratory. These drugs include: Amphetamines, Methamphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Opiates, Phencyclidine, Tetrahydrocannabinols and Tricyclic anti-depressants.
27. Evidence of any condition that, in the opinion of the clinical investigator, might interfere with the evaluation of the study objectives or pose excessive risks to participants.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 0
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 286212 0
Name [1] 286212 0
The Atlantic Philanthropies
Address [1] 286212 0
The Atlantic Philanthropies
Suite 106
12 Waters Road
Neutral Bay
NSW 2089
Country [1] 286212 0
Primary sponsor type
Griffith University
c/- Chris Davis
Griffith University, Gold Coast Campus
Institute for Glycomics, Building G26
Parklands Drive
Southport, 4222
Secondary sponsor category [1] 285022 0
Name [1] 285022 0
Address [1] 285022 0
Country [1] 285022 0

Ethics approval
Ethics application status
Ethics committee name [1] 288288 0
The Gold Coast Hospital and Health Service Human Research Ethics Committee
Ethics committee address [1] 288288 0
8 Little High Street
QLD 4215
Ethics committee country [1] 288288 0
Date submitted for ethics approval [1] 288288 0
Approval date [1] 288288 0
Ethics approval number [1] 288288 0

Brief summary
This study is examining the infectivity of a Plasmodium falciparum NF54 malaria cell bank in humans. Participants will receive a single inoculum of the malaria cell bank, which consists of human red blood cells containing P. falciparum NF54 malaria parasites. Following administration of the inoculum, we will measure the growth of the malaria parasites in the blood-stream and then administer anti-malarial treatment (Riamet) according to specific criteria (based on the number of parasites in the blood as well as clinical signs/symptoms of malaria). We will also be assessing the safety of the inoculum and also the way the immune system responds to it. Determining the infectivity and safety of the malaria cell bank is important as it will form a critical part of future clinical trials investigating the effectiveness of a new malaria vaccine that is currently being developed.
Trial website
Not applicable
Trial related presentations / publications
The data from this study is currently being prepared for publication
Public notes

Principal investigator
Name 34879 0
Prof Michael Good
Address 34879 0
c/- Griffith University, Gold Coast Campus, Institute for Glycomics, Building G26, Parklands Drive, Southport, 4215, QLD
Country 34879 0
Phone 34879 0
61 7 555 29435
Fax 34879 0
61 7 555 28098
Email 34879 0
Contact person for public queries
Name 18126 0
Dr Dr Danielle Stanisic
Address 18126 0
C/- Griffith University, Gold Coast Campus
Institute for Glycomics, Building G26
Parklands Drive,
SOuthport, 4222
Country 18126 0
Phone 18126 0
61 7 555 28051
Fax 18126 0
61 7 555 28098
Email 18126 0
Contact person for scientific queries
Name 9054 0
Prof Professor Michael Good
Address 9054 0
C/- Griffith University, Gold Coast Campus
Institute for Glycomics, Building G26
Parklands Drive,
SOuthport, 4222
Country 9054 0
Phone 9054 0
61 7 555 28051
Fax 9054 0
61 7 555 28098
Email 9054 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary